# US 2019/0376028 A1 · Definitive endoderm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376028 A1
- Document ID: US20190376028A1
- Status: Published application
- Kind: A1
- Application number: 16/539,966
- Filed: 2019-08-13
- Published: 2019-12-12
- Earliest claimed: 2003-12-23
- Assignees: ViaCyte, Inc.
- Applicants: ViaCyte, Inc.
- Inventors: Kevin Allen D'Amour; Alan D. Agulnick; Emmanuel E. Baetge
- Web page: https://patentgrep.com/patent/US20190376028A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/068: {Stem cells; Progenitors}
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/415: Wnt; Frizzeled
- C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.

## Claims

### Claim 1

An in vitro method of making a cell population comprising definitive endoderm cells, the method comprising:
(a) obtaining a cell population comprising human pluripotent stem cells in medium comprising no serum or serum replacement; and
(b) providing the cell population comprising human pluripotent stem cells with a TGFβ super family member,
thereby producing a cell population comprising definitive endoderm cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TGFβ super family member is activin A.

### Claim 3 (depends on 2)

The method of claim 2, comprising providing the cell population comprising human pluripotent stem cells with about 10-100 ng/ml activin A.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell population comprising definitive endoderm further comprises mesendoderm.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises providing a medium comprising less than about 10% volume/volume (v/v) serum about 24 hours after the TGFβ super family member is provided.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method further comprises providing a medium comprising less than about 2% volume/volume (v/v) serum about 24 hours after the TGFβ super family member is provided.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method further comprises providing a medium comprising less than about 2% volume/volume (v/v) serum about 24 hours after the TGFβ super family member is provided.

### Claim 8 (depends on 1)

The method of claim 1, further comprising providing the cell population comprising human pluripotent stem cells with a WNT protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein the WNT protein in Wnt3A.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cell population comprising definitive endoderm cells is substantially free of cells derived from the ectoderm lineage.

### Claim 11

An in vitro method of making a cell population comprising definitive endoderm cells comprising:
(a) obtaining a cell population comprising human pluripotent stem cells in a medium comprising less than about 10% serum; and
(b) providing the cell population with a TGFβ super family member,
thereby producing a cell population comprising definitive endoderm cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the TGFβ super family member is activin A.

### Claim 13 (depends on 12)

The method of claim 12, comprising providing the cell population comprising human pluripotent stem cells with about 10-100 ng/ml activin A.

### Claim 14 (depends on 11)

The method of claim 11, wherein the cell population comprising definitive endoderm further comprises mesendoderm.

### Claim 15 (depends on 11)

The method of claim 11, wherein the media comprises less than about 2% (v/v) serum.

### Claim 16 (depends on 11)

The method of claim 11, wherein the media comprises less than about 0.5% (v/v) serum.

### Claim 17 (depends on 11)

The method of claim 11, further comprising providing the cell population comprising human pluripotent stem cells with a WNT family member.

### Claim 18 (depends on 11)

The method of claim 11, wherein the WNT family member in Wnt3A.

### Claim 19 (depends on 11)

The method of claim 11, wherein the cell population comprising definitive endoderm cells is substantially free of cells derived from the ectoderm lineage.

### Claim 20

A method of differentiating human pluripotent cells, said method comprising culturing a population of pluripotent human cells in a medium comprising no serum or serum replacement and a TGFβ superfamily growth factor thereby differentiating the human pluripotent cells.
